Q3 2017 13F Holders as of 30 Sep 2017
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
104,661,494
-
Total 13F shares
-
27,433,692
-
Share change
-
-84,839
-
Total reported value
-
$754,721,335
-
Put/Call ratio
-
105%
-
Price per share
-
$27.55
-
Number of holders
-
84
-
Value change
-
-$1,638,080
-
Number of buys
-
40
-
Number of sells
-
37
Institutional Holders of Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) as of Q3 2017
As of 30 Sep 2017,
Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) was held by
84 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
27,433,692 shares.
The largest 10 holders included
Essex Woodlands Health Ventures, Inc., JPMORGAN CHASE & CO, FRANKLIN RESOURCES INC, WELLINGTON MANAGEMENT GROUP LLP, BlackRock Inc., ArrowMark Colorado Holdings LLC, Bank of New York Mellon Corp, Polar Capital LLP, VANGUARD GROUP INC, and CANADA PENSION PLAN INVESTMENT BOARD.
This page lists
84
institutional shareholders reporting positions in this security
for the Q3 2017 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.